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.2013.02.Abstract Objective: This study was conducted to compare two techniques of sedation for obese
patients undergoing ERCP, using either ketofol or fentanyl–propofol as regards propofol consump-
tion, recovery time, patients’ satisfaction, and sedation-related adverse events.
Materials and methods: Two hundred obese patients were randomly allocated to one of two
groups; ketamine/propofol (ketofol) group KP (n= 100) or fentanyl/propofol group FP
(n= 100). The level of sedation was adjusted to achieve a Ramsay Sedation Scale (RSS) score of 5.
Results: Total dose of propofol consumed was signiﬁcantly higher in group FP compared with
group KP (97.08 ± 23.31 mg and 57.71 ± 16.97) mg. Recovery time was slightly longer in group
KP compared with group FP (11.19 ± 2.59 min and 9.43 ± 1.23 min, respectively), time needed
to achieve Aldrete Recovery Scale Score of 9 was comparable in both groups, and sedation-related
side effects as hypotension, bradycardia, apnea, and reduction of SpO2 were more signiﬁcant in the
FP group.
In conclusion: Ketamine/propofol combination 1:4 provided better sedation quality than fentanyl/
propofol combination with less side effects and can be safely used for sedating obese patients under-
going ERCP.
ª 2013 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license..com (R. Hasanein).
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Endoscopic retrograde cholangiopancreatography (ERCP) is a
lengthy and potentially uncomfortable procedure that needs
moderate to deep sedation or even general anesthesia to facil-
itate high success rate and avoid patient’s discomfort [1,2].
Anesthetic management of ERCP can be challenging due to
different factors; remote location, prone position, head of
the patient is far away from the anesthetist, lengthy procedure,
shared airway, and less familiar environment.osting by Elsevier B.V. Open access under CC BY-NC-ND license.
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challenging; they have reduced total lung volume, reduced
functional residual capacity (FRC), and reduced vital capacity.
These decreases in lung volumes decrease exponentially with
the increase in body mass index (BMI) [3]. Moreover, the ven-
tilation/perfusion mismatches can occur more easily in these
patients. In addition, obstructive sleep apnea is commonly de-
tected during deep sleep in fatty adults [4].
There are three levels of the severity degree of obesity; over-
weight: BMI > 25, obese: BMI > 30, and morbidly obese:
BMI > 35.
Propofol, a phenol derivative, is a short-acting intrave-
nously administered sedative and hypnotic agent [5]. It has
been used frequently over the past two decades as a sedative
agent for endoscopic procedures [6]. However, propofol can
cause deep sedation or even dangerous side effects that need
cardiopulmonary support [7].
Ketamine, an NMDA receptor antagonist and has also been
found to bind to opioid receptors and sigma receptors, leads to a
condition called ‘‘dissociative anesthesia’’ [8]. It causes amnesia,
analgesia and maintains spontaneous breathing [9,10]. But its use
as a single sedative agent has been limited by its propensity to cause
vivid and frightening emergent reactions [11], sympathomimetic ef-
fects, and vomiting when given in sedating doses [12].
A combination of ketamine and propofol in the same syr-
inge (ketofol) for procedural sedation and analgesia (PSA)
was proved to be safe and preserve sedation efﬁcacy with min-
imizing their respective side effects. Ketamine and propofol gi-
ven in combination have offered effective sedation for spinal
anesthesia and for gynecologic, ophthalmologic, and cardio-
vascular procedures in all age groups [13].
This study was aimed to compare between two regimens of
sedation; ketofol versus fentanyl/propofol in overweight and
obese patients undergoing ERCP regarding recovery time, pa-
tients’ satisfaction, and sedation-related adverse events. Mor-
bidly obese patients are out of our scope, as preemptive
endotracheal intubation may be appropriate for them prior
to performing an ERCP.
2. Materials and methods
After obtaining ethical committee approval and written in-
formed consent, a double-blind randomized study was done
in Saad specialist hospital, Saudi Arabia; on 200 obese patients
scheduled for ERCP during February 2009 to February 2011,
aged from 18 to 70 years with BMI 25-35 and ASA physical
status I, II, or III. Pregnant patients, morbidly obese patients,
patients with chronic obstructive pulmonary disease, compli-
cated airway, ASA physical classiﬁcation IV–V, history of al-
lergy or contraindications to the drugs used in the study,
emergency need for ERCP, those whose informed consent
could not be signed, and those with possible complex ERCP
were excluded from this study. Patients were randomly allo-
cated by the ‘‘sealed envelope technique’’ to one of two groups
and received either of the following two regimens:
Ketofol group KP (n= 100).
Fentanyl/propofol group FP (n= 100).
Sealed envelope was broken when the patient was in the
ERCP room. The study drugs were prepared by an assistant
who was not involved in the clinical management of the studypatients, and bolus drugs are given according to the lean body
weight, while continuous infusion was adjusted according to
the total body weight.
For ketofol (KP) group, a bolus dose of 10 ml normal sal-
ine followed by ketofol infusion (ketamine: propofol concen-
tration 1:4) prepared in 50 ml syringe, by mixing 40 ml
propofol 1% (10 mg/ml) with 2 ml ketamine (50 mg/ml) and
8 ml dextrose 5% (each ml contained 8 mg propofol and
2 mg ketamine).
In case of group FP, a bolus of fentanyl 1.5 lg/kg i.v., the
volume of which was made to 10 ml followed by 40 ml propo-
fol 1%, was mixed with 10 ml dextrose 5%, so that each mil-
liliter contained 8 mg of propofol.
The anesthesiologist who gave the drugs and assessed the
parameters was blinded to the randomization process and to
the study drug identity but not to concentration of the drug
in the syringes (mg/ml). Both bolus and maintenance doses will
be given using syringe pump (B/Braun). Both the interven-
tional drugs were given as an initial bolus dose of 0.5 mg/kg
propofol IV (considering the syringes contained only propofol
for simplicity). Then, infusion was started at the rate of 50 lg/
kg/min. The level of sedation was assessed at 1–3 min intervals,
and the infusion rate was adjusted accordingly to achieve a
Ramsay Sedation Scale (RSS) score of 5 [14] (Table 1).
On arrival to the radiology suite, intravenous access was
established, and (0.02–0.03) mg/kg midazolam and an infusion
with lactated Ringer’s solution were started. Routine monitor-
ing included an electrocardiogram (ECG), noninvasive arterial
blood pressure (NIBP), pulse oximetry (SpO2), and end tidal
carbon dioxide (EtCO2) and respiratory rate (RR) measured
through oxygen delivery nasal prongs. Supplemental oxygen
was delivered at 3 l/min.
Any desaturation or apnea were recorded when the SpO2
dropped to <90% or recorded cessation of respiration for
15 s or more, respectively, and were managed by supporting
the airway and/or assisting ventilation. Hypotension was con-
sidered when the mean arterial pressure (MAP) decreased by
>20% of the baseline MAP and managed by ﬂuid bolus
and/or vasopressors. Bradycardia was considered when heart
rate was less than 55 beats/min and managed with atropine
20 mcg/kg i.v. Any movement of the patient was treated with
increase in the study drug infusion rate. The study drug infu-
sion was discontinued at the end of the procedure, and the
total drug requirements were noted. The recovery time was
considered as the time from discontinuation of infusion of
the study drug till achievement of RSS score of 3 was re-
corded, and patients were transferred to the recovery room.
The recovery nurse was blinded to the study medication re-
ceived by the patients. The incidence of postoperative nausea
and vomiting (PONV) or any other adverse events (e.g., hal-
lucinations, agitation, or pain) were recorded and were man-
aged accordingly. The patient’s vital signs were assessed at
5 min intervals. Patients were discharged from the recovery
room after attaining an Aldrete Recovery Scale Score of 9–
10 (Table 2) [15]. Time taken to achieve this score was
recorded.
Patient’s satisfaction was assessed using a 100-mm visual
analog scale (VAS) (0 = least satisﬁed, 100 = most satisﬁed).
The patients rated their satisfaction by making a vertical mark
on the 100-mm line. Only patients with scoreP75 were consid-
ered satisﬁed. The exact question was ‘‘Are you satisﬁed with
your sedation?’’
Table 3 Patients’ characteristics, procedure’s duration and
indications.
Variables Group KP
(n= 100)
Group FP
(n= 100)
P value
Gender (male/female) 49/51 50/50 0.888
Age (years)a 57.67 ± 13.3 56.93 ± 11.9 0.679
BMIa 29.6 ± 3.53 28.9 ± 4.42 0.217
Procedure’s duration (min) 31.61 ± 17.65 27.88 ± 14.38 0.099
ASA classiﬁcation (%) 0.937
I 16 17
II 61 62
III 23 21
Indication (%) 0.821
Cholethiasis 45 43
Biliary stricture (tumor) 42 46
Others 13 11
a Data are given as mean ± SD.
Table 4 Mean dose of propofol and recovery times.
Variables Group KP
(n= 100)
Group FP
(n= 100)
P value
Total dose of propofol (mg) 57.71 ± 16.97 97.08 ± 23.31 <0.01*
Recovery time (min) 11.19 ± 2.59 9.43 ± 1.23 <0.01*
Time to achieve Aldrete
Score 9 (min)
13.28 ± 5.14 12.58 ± 5.41 0.349
Data are given as mean ± SD.
* P value < 0.05.
Table 2 The Modiﬁed Aldrete Scoring System [15].
Activity: able to move voluntarily or on command
4 extremities 2
2 extremities 1
0 extremities 0
Respiration
Able to deep breathe and cough freely 2
Dyspnea, shallow or limited breathing 1
Apneic 0
Circulation
BP± 20 mm of preanesthetic level 2
BP ± 20–50 mm of preanesthesia level 1
BP ± 50 mm of preanesthesia level 0
Consciousness
Fully awake 2
Arousable on calling 1
Not responding 0
O2 saturation
Able to maintain O2 saturation >92% on room air 2
Needs O2 inhalation to maintain O2 saturation >90% 1
O2 saturation< 90% even with O2 supplementation 0
Table 1 Ramsay Sedation Scale.
Sedation
level
Description
1 Patient is anxious, agitated or restless, or both
2 Patient is cooperative, oriented, and tranquil
3 Patient responds only to commands
4 Patient responds to light glabellar tap or loud
auditory stimulus
5 Patient has a sluggish response to light glabellar
tap or loud auditory stimulus
6 No response
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Data were statistically described in terms of mean ± standard
deviation (±SD), or frequencies (number of cases) and per-
centages when appropriate. Comparison of numerical vari-
ables between the study groups was done using Student’s t-
test for independent samples. For comparing categorical data,
Chi square (v2) test was performed. Yates correction equation
was used instead when the expected frequency is less than 5. P
values less than 0.05 were considered statistically signiﬁcant.
All statistical calculations were done using computer programs
SPSS (Statistical Package for the Social Science; SPSS Inc.,
Chicago, IL, USA) version 15 for Microsoft Windows.
4. Results
Two hundred patients were enrolled in this study and com-
pleted it. There were no differences in the baseline characteris-
tics of patients including gender, age, body mass index (BMI),
procedure’s duration, type of ERCP and ASA physical status
classiﬁcation (Table 3).
Total dose of propofol consumed was signiﬁcantly higher in
group FP compared with group KP (97.08 ± 23.31 mg and
57.71 ± 16.97) mg, respectively, P< 0.01). Recovery timewas slightly longer in group KP compared with group FP
(11.19 ± 2.59 min and 9.43 ± 1.23 min, respectively,
P< 0.01). The time needed to achieve Aldrete Recovery Scale
Score of 9 was comparable in both groups (13.28 ± 5.14 min
and 12.58 ± 5.41 min, P= 0.007) in the KP and FP, respec-
tively (Table 4).
In this study, hypotension occurred in three patients (3%)
in group KP compared with 12 (12%) in group FP, while
hypertension was recorded only in two patients in group KP.
Bradycardia was found in nine patients (9%) in group FP
compared with one (1%) in group KP. Tachycardia occurred
in three patients (3%) in group KP compared with one (1%)
patient in FP group. Apnea occurred in two patients (2%) in
group KP compared with 10 patients (10%) in group FP
(Table 5).
Emergence reaction (agitation) occurred only in two pa-
tients (2%) in group KP and treated by i.v. midazolam
0.05 mg/kg. PONV occurred in three patients (3%) in group
KP and in one patient (1%) in group FP, treated by i.v. ondan-
setron 0.1 mg/kg.
Patients’ satisfaction was comparable in both groups; 90
patients in group KP had score P75 versus 91 patients in
the group FP. The satisfaction score in group KP was (90%)
and in group FP was (91%) (Table 5).
5. Discussion
Overweight and obesity are increasingly common problems
worldwide. Many of these patients are at high risk for the
ERCP procedure and for sedation [3,4,16].
Table 5 Sedation-related side effects and patients satisfaction (n, %).
Variables Group KP (n= 100) Group FP (n= 100) P value
Hypotension 3 (3%) 12(12%) 0.032*
Hypertension 2 (2%) 0 0.477
Bradycardia 1 (1%) 9 (9%) 0.023*
Tachycardia 3 (3%) 1 (1%) 0.614
Apnea 2 (2%) 10(10%) 0.037*
SpO2 < 90% 0 7 (7%) 0.021
*
Movement 4 (4%) 6 (6%) 0.746
Agitation 2 (2%) 0 0.477
PONV 3 (3%) 1(1%) 0.614
Patients’ satisfaction 90 (90%) 91(91%) 1.000
* Statistically signiﬁcant, P value < 0.05.
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tors for hypoxemia [17,18].
A multivariate analysis was carried out on variables which
included BMI to determine its effect on hypoxemia, and they
found a non-linear relation between incidence of hypoxemia
and BMI. If BMI is 20 or less, odd ratio of hypoxemia kept
nearly constant during GI endoscopy and did not change with
BMI. But when BMI value is more than 20, the higher BMI
value, the higher odd ratio of hypoxemia [19].
Our goal in this study was to provide an adequate level of
sedation while minimizing pain and anxiety, minimizing the
adverse drug-related events, controlling behavior, and main-
taining a stable cardiovascular and respiratory status.
Continuous infusion technique was used in our study to
maintain a steady state sedation level. The RSS score has been
used to assess the level of sedation. Serious complications with
propofol-based sedation as respiratory and cardiovascular side
effects can occur and need to be rapidly recognized and appro-
priately managed.
In our study, higher incidence of hypotension, bradycardia,
apnea, and desaturation has been observed in group fentanyl–
propofol than in the ketofol group, and the ketamine–propofol
combination is thought to act by antagonizing the side effects of
each other.
In this study, the total dose of propofol needed to achieve a
deep sedation level was lower in the ketofol group (57.71 ±
16.97) than in the fentanyl–propofol group (97.08 ± 23.31),
which contributed to the lower incidence of propofol seda-
tion-related adverse effects.
In the present study, the recovery time and time to dis-
charge from the recovery room in the ketofol group were with-
in the acceptable range (11.19 ± 2.59) and (13.28 ± 5.14),
although it was slightly longer than that of group fentanyl–
propofol (9.43 ± 1.23) and (12.58 ± 5.41), respectively.
Slower clearance of ketamine in comparison with fentanyl is
probably responsible for this.
Although there is a higher incidence of emergence agitation
and PONV in the ketofol group compared with the fentanyl–
propofol group, this incidence rate is much lower than the usual
incidence rate of ketamine alone. Emergence reactions and vom-
iting are signiﬁcant adverse effects of ketamine usage, occurring
more in adults than in children [20]. Emergence phenomena as
high as 50% in adults have also been found by others [21].
The lower concentration of ketamine to propofol (1:4),
counteraction of propofol, with its sedative and antiemetic ef-
fects, and the premedication with midazolam helped to reduce
the overall incidence rates of these adverse events of ketamine.Ketamine–propofol combinations in different ratios (1:1–1:5)
havebeenusedbymanyauthors before [22–24].All these combina-
tions revealed hemodynamic stability. Increased discharge time
was found when higher proportion of ketamine was used. Akin
and colleagues found better maintenance of MAP without pro-
longing recovery in the ketamine–propofol (1:3) combination
group than in the propofol monotherapy group [25].
The ratio of propofol to ketamine in preparing ketofol infu-
sion is a challenge; Daabis et al. [13] compared the safety and
efﬁcacy of different concentrations of ketofol in procedural
operations in children and concluded that propofol combined
with ketamine (4:1) infusion for procedural operations resulted
into adequate sedation and analgesia without hemodynamic
and respiratory depression or psychotomimetic side effects
and appears to be useful and can be safely used for procedural
operations in the ambulatory setting.
Akin et al. [23] compared propofol (1.5 mg/kg) to propofol
(1.5 mg/kg) and ketamine (0.5 mg/kg) in a ratio of 3:1 and re-
ported no cases of desaturation with ketofol, but with propofol
4/30 had desaturation and 6/30 had apnea, blood pressure and
heart rate were signiﬁcantly lower with propofol than ketofol
and reported that the addition of low dose ketamine to propo-
fol reduced the risk of respiratory depression and the need for
repeat medication administration.
5.1. In conclusion
Ketamine–propofol combination (1:4) provided better seda-
tion quality than fentanyl/propofol combination, with less
hemodynamic and respiratory depression and appears to be
a safe and useful technique for sedating obese patients under-
going ERCP.
5.2. Limitations of this study
Wide range of age of the patients; drug requirements, recovery
time, and side effects can be related to age. Further studies are
needed in a larger group of obese patients with different con-
centration of ketamine:propofol combinations.
References
[1] Biring MS, Lewis MI, Liu JT, et al. Pulmonary physiologic
changes of morbid obesity. Am J Med Sci 1999;318:293–7.
[2] Lichtenstein DR, Jagannath S, Baron TH, et al. Sedation and
anesthesia in GI endoscopy. Gastrointest Endosc
2008;68(5):815–26.
Ketamine/propofol versus fentanyl/propofol retrograde cholangiopancreatography (ERCP) 211[3] Dumonceau JM, Riphaus A, Aparicio JR, et al. European
Society of Gastrointestinal Endoscopy, European Society of
Gastroenterology and Endoscopy Nurses and Associates, and
the European Society of Anaesthesiology Guideline:
Nonanesthesiologist administration of propofol for GI
endoscopy. Endoscopy 2010;42(11):960–74.
[4] See CQ, Mensah E, Olopade CO. Obesity, ethnicity, and sleep
disordered breathing: medical and health policy implications.
Clin Chest Med 2006;27:521–33.
[5] Miner JR, Burton JH. Clinical practice advisory. Emergency
department procedural sedation with propofol. Ann Emerg Med
2007;50(2):182–7.
[6] Bryson EO, Sejpal D. Anesthesia in remote locations: radiology
and beyond, international anesthesiology clinics:
gastroenterology: endoscopy, colonoscopy, and ERCP. Int
Anesthesiol Clin 2009;47:69–80.
[7] Cote´ GA, Hovis RM, Ansstas MA, et al. Incidence of sedation-
related complications with propofol use during advanced
endoscopic procedures. Clin Gastroenterol Hepatol
2010;8:137–42.
[8] Harrison N, Simmonds M. Quantitative studies on some
antagonists of N-methyl d-aspartate in slices of rat cerebral
cortex. Br J Pharmacol 1985;84(2):38191.
[9] Krauss B, Green SM. Procedural sedation and analgesia in
children. Lancet 2006;367:766–80.
[10] Warncke T, Stubhaug A, Jørum E. Ketamine, an NMDA
receptor antagonist, suppresses spatial and temporal properties
of burn-induced secondary hyperalgesia in man: a double-blind,
cross-over comparison with morphine or placebo. Pain
1997;72:99–106.
[11] Green SM, Rothrock SG, Lynch EL, et al. Intramuscular
ketamine for pediatric sedation in the emergency department:
safety proﬁle in 1022 cases. Ann Emerg Med 1998;31:688–97.
[12] Roback MG, Wathen JE, Bajaj L, et al. Adverse events
associated with procedural sedation and analgesia in a
pediatric emergency department: a comparison of parenteral
drugs. Acad Emerg Med 2005;12:508–13.
[13] Daabis M, Elsherbiny M, Alotibi R. Assessment of different
concentration of ketofol in procedural operation. BMJ
2009;2(1):27–31.[14] Grifﬁths RD, Jones C. Recovery from intensive care. Br Med J
1999;319(427):9.
[15] Aldrete JA. The post anesthesia recovery score revisited. J Clin
Anesth 1995;7:89–91 [letter].
[16] Dhariwal A, Plevris JN, Lo NT, et al. Age, anemia, and obesity-
associated oxygen desaturation during upper gastrointestinal
endoscopy. Gastrointest Endosc 1992;38(6):684–8.
[17] Muller S, Prolla JC, Maguilnik I, et al. Predictive factors of
oxygen desaturation of patients submitted to endoscopic
retrograde cholangiopancreatography under conscious
sedation. Arq Gastroenterol 2004;41(3):162–6.
[18] Qadeer MA, Vargo JJ, Khandwala F, et al. Propofol versus
traditional sedative agents for gastrointestinal endoscopy: a
meta-analysis. Clin Gastroenterol Hepatol 2005;3(11):1049–56.
[19] Yanhua L, Huj-Huj L, Changhong Y, et al. Pre-existing
diseases of patients increase susceptibility to hypoxemia during
gastrointestinal endoscopy. PloS One 2012;7(5):e37614.
[20] Green SM, Krauss B. Clinical practice guideline for emergency
department ketamine dissociative sedation in children. Ann
Emerg Med 2004;44:460–71.
[21] Chudnofsky CR, Weber JE, Stoyanoff PJ, et al. A combination
of midazolam and ketamine for procedural sedation and
analgesia in adult emergency department patients. Acad Emerg
Med 2000;7:228–35.
[22] Badrinath S, Avramov MN, Shadrick M, et al. The use of a
ketamine–propofol combination during monitored anesthesia
care. Anesth Analg 2000;90:858–62.
[23] Akin A, Esmaoglu A, Tosun Z, et al. Comparison of propofol
with propofol–ketamine combination in paediatric patients
undergoing auditory brainstem response testing. Int J Pediatr
Otorhinolaryngol 2005;69:1541–5.
[24] Willman EV, Andolfatto G. A prospective evaluation of
‘‘ketofol’’ (ketamine/propofol combination) for procedural
sedation and analgesia in the emergency department. Ann
Emerg Med 2007;49:23–30.
[25] Akin A, Esmaoglu A, Guler G, et al. Propofol and propofol
ketamine in pediatric patients undergoing cardiac
catheterization. Pediatr Cardiol 2005;26:553–7.
